[Form 4] Darden Restaurants, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Rhythm Pharmaceuticals, Inc. (RYTM) – Form 4 insider filing

Director Camille L. Bedrosian reported the vesting of 4,000 restricted stock units (RSUs) on 18 June 2025 (transaction code M). Upon settlement, the RSUs converted into an equal number of common shares at no cash cost, increasing the director’s directly held common-stock position to 7,000 shares. No derivative securities remain outstanding from this grant, and no sales were disclosed. The filing was signed by attorney-in-fact Stephen Vander Stoep on 23 June 2025.

The transaction reflects routine equity compensation vesting rather than discretionary open-market buying or selling. Given the modest share count and automatic nature of the conversion, the event is considered immaterial to the company’s overall share structure and does not signal a change in strategic outlook or insider sentiment.

Insights

Equity Compensation Analyst

TL;DR: Routine RSU vest; small, neutral impact.

The Form 4 shows a straightforward RSU vest for 4,000 shares. Such conversions are non-discretionary and cashless, so they do not represent insider conviction the way open-market purchases might. Bedrosian’s total direct holdings rise to 7,000 shares, a negligible fraction of RYTM’s ~56 million shares outstanding. There is no dilution because the shares were already included in fully diluted counts via equity plans. From a compensation perspective, this is ordinary course and neutral for valuation.

Corporate Governance Specialist

TL;DR: Standard director equity vesting; governance normal.

The filing confirms compliance with Section 16 reporting deadlines and appropriate use of power of attorney. No 10b5-1 plan was cited, implying the transaction was automatic under the company’s equity plan. There are no red flags such as simultaneous sales or large net share disposals. Therefore, the event is not impactful for governance risk assessments.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Broad Matthew R

(Last) (First) (Middle)

1000 DARDEN CENTER DRIVE

(Street)

ORLANDO FL 32837

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DARDEN RESTAURANTS INC [ DRI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2025		M		6,949	A	$124.24	21,316.233(1)	D
Common Stock	06/30/2025		S		6,949	D	$218.0049(2)	14,367.233(1)	D
Common Stock	07/01/2025		M		733	A	$124.24	15,100.233(1)	D
Common Stock	07/01/2025		S		733	D	$218.4983(3)	14,367.233(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$124.24	06/30/2025		M			6,949	(4)	07/24/2029	Common Stock	6,949	$0.0000	733	D
Stock Option (Right to Buy)	$124.24	07/01/2025		M			733	(4)	07/24/2029	Common Stock	733	$0.0000	0.0000	D

Explanation of Responses:

1. Includes shares acquired pursuant to the Darden Restaurants, Inc. Employee Stock Purchase Plan and dividend reinvestment feature of the Plan.

2. This transaction was executed in multiple trades at prices ranging from $218.00 to $218.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $218.36 to $218.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This option vested in two equal annual installments beginning on July 24, 2022.

	A. Noni Holmes-Kidd, Attorney-in-fact for Broad, Matthew R.	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the RYTM Form 4 filed on 23-Jun-2025 disclose?

Director Camille L. Bedrosian’s 4,000 RSUs vested on 18-Jun-2025, converting into 4,000 common shares.

How many RYTM shares does Camille L. Bedrosian now own?

After the transaction, the director holds 7,000 shares of Rhythm Pharmaceuticals common stock directly.

Was there any sale of RYTM stock in this Form 4?

No. The filing shows an acquisition via RSU vesting; no shares were sold.

What does transaction code "M" mean in a Form 4?

Code M indicates the conversion or exercise of a derivative security—here, RSUs converting to common stock.

Is the 4,000-share RSU vesting material to RYTM investors?

Given RYTM’s multi-million-share float, the impact is immaterial and viewed as routine compensation.